SLU-PP-332
SLU-PP-332 is a synthetic small molecule developed at Saint Louis University that acts as a pan-agonist of the estrogen-related receptor (ERR) family — ERRα, ERRβ, and ERRγ. It is being researched as a potential "exercise mimetic," capable of producing many of the metabolic and endurance benefits of exercise at the cellular level. This oral capsule format provides a convenient, injection-free administration route, making SLU-PP-332 accessible to researchers who prefer not to use injectable compounds. Available in 250 mcg and 300 mcg capsule strengths for flexible dosing protocols.
SLU-PP-332 activates the estrogen-related receptor (ERR) family, a group of orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure. Despite the name, ERRs do not bind estrogen — they are constitutively active transcription factors that control genes involved in fatty acid oxidation, oxidative phosphorylation, and slow-twitch muscle fiber formation. By directly activating all three ERR isoforms, SLU-PP-332 mimics many of the transcriptional changes that occur during endurance exercise, including increased mitochondrial density, enhanced fatty acid utilization, and a shift toward oxidative metabolism. In published mouse research, this translated to significant endurance improvements and resistance to diet-induced obesity.
- Activates the ERR pathway to mimic many transcriptional effects of endurance exercise
- Convenient oral capsule format with no injection required
- Increases mitochondrial biogenesis and oxidative capacity
- Promotes fatty acid oxidation and metabolic flexibility
- Demonstrated significant endurance improvements in animal research
- Shows resistance to diet-induced obesity in mouse models
- Supports a shift toward slow-twitch oxidative muscle fiber profile
- May enhance metabolic flexibility and substrate utilization
- Does not stimulate the central nervous system like traditional stimulants
- Potential research applications in metabolic syndrome and obesity
- Available in flexible 250 mcg and 300 mcg capsule strengths
- Limited human safety data; almost all research is preclinical
- Theoretical effects on cardiac tissue due to ERRα expression in heart muscle
- Potential effects on bone metabolism via ERR pathway activation
- Unknown long-term effects on hormonal and reproductive systems
- Possible mild gastrointestinal effects with oral administration
- Oral bioavailability of SLU-PP-332 has not been fully characterized
- Not approved for human use; sold strictly for research purposes
- No established human dosing protocols or pharmacokinetic data
- Long-term safety profile in humans is entirely unknown
- Consult a qualified medical professional before any use
One of the most heavily studied exercise mimetic compounds currently in research Oral capsule format provides convenient, needle-free administration Pairs theoretically with mitochondrial peptides like SS-31 and MOTS-c May complement fat-loss compounds like HGH Frag 176-191 or Tesamorelin Stacks with cardiovascular and endurance-focused research compounds Often researched alongside endurance training protocols Typical research dosing: 250-600 mcg daily, single or split dose Some users prefer pre-workout dosing for endurance research applications Morning administration common; can be taken with or without food Store capsules in cool, dry conditions away from direct light This is an emerging research compound with limited human data Consider starting at 250 mcg daily and titrating based on research goals
Select your preferred supplier and add to cart. Prices shown include VAT.
| Supplier / Lab | Strength / Volume | Price | Availability | |
|---|---|---|---|---|
|
IP
iPharma
South Africa
|
250mcg
60 Caps
|
R600
|
In Stock | |
|
HE
Healthy-U
South Africa
|
300mcg
60 Caps
|
R750
|
In Stock |